Treatment with statins reduces the rate of cardiovascular events in high-risk patients, but residual risk persists. At least part of that risk may be attributable to atherogenic dyslipidemia characterized by low HDLc (≤40mg/dL) and high triglycerides (triglycerides ≥150mg/dL) [1]. There is mounting evidence that atherogenic dyslipidemia is an independent predictor of high cardiovascular risk and stroke.
